Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Jennifer Clarke (ucsf)
Headshot of Jennifer Clarke
Jennifer Clarke

Description

Summary

The current study will test the ability and likelihood of successfully implementing individualized combination treatment recommendations for adult patients with surgically-resectable recurrent glioblastoma in a timely fashion. Collected tumor tissue and blood will be examined using a new diagnostic testing called University of California, San Francisco (UCSF) 500 Cancer Gene Panel which is done at the UCSF Clinical Cancer Genomics Laboratory. The UCSF 500 Cancer Gene Panel will help identify genetic changes in the DNA of a patient's cancer, which helps oncologists improve treatment by identifying targeted therapies.

Official Title

Pilot Study Testing Feasibility of Individualized Therapy for Recurrent Glioblastoma

Details

Keywords

Recurrent Glioblastoma, Glioblastoma, Adult Glioblastoma, Glioma, Precision Medicine, Specialized Tumor Board, Recurrence, Individualized therapy

Eligibility

Location

  • University of California San Francisco
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Jennifer Clarke (ucsf)
    Jennifer L. Clarke, MD, MPH Professor of Clinical Neurology and Neurological Surgery Division of Neuro-Oncology Principal Investigator, Brain Tumor Research Center

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jennifer Clarke
ID
NCT03681028
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 30 people participating
Last Updated